Form 10-Q Hims & Hers Health, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Hims and Hers (HIMS) PT Lowered to $14 at Jefferies
May 7, 2024 4:03 PM EDTJefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $14.00 (from $15.00) while maintaining a Hold rating.
The analyst comments "We are updating our model following 1Q results. The updated model reflects the company's impressive profitability ramp... More
Hims and Hers (HIMS) PT Raised to $16 at Deutsche Bank
May 7, 2024 5:24 AM EDTDeutsche Bank analyst George Hill raised the price target on Hims and Hers (NYSE: HIMS) to $16.00 (from $14.00) while maintaining a Hold rating.
The analyst comments "Based on the strong momentum in Q1, management raised the 2024 revenue guidance by $30 million at the... More

